

Amendments to the claims:

The following claim listing will replace all previous claim listings in the application.

1-7 (Canceled)

8. (Previously presented) The method of Claim 9, wherein the column is a N-hydroxysuccinimide (NHS-) – activated highly cross linked 4% agarose column.

9. (Currently amended) A method of treating a subject having systemic lupus erythematosus comprising extracorporeal treatment of plasma from the subject by affinity ~~absorption~~ adsorption column chromatography, wherein the column comprises a peptide having an amino acid sequence as set forth in SEQ. ID. NO. 1, and returning plasma so treated to the ~~patient~~ subject.

10. (Previously presented) The method of Claim 9, wherein the peptide is coupled to the column using a coupling buffer.

11. (Currently amended) A method of treating a subject having systemic lupus erythematosus comprising extracorporeal treatment of plasma from the subject by affinity ~~absorption~~ adsorption column chromatography, wherein the column consists essentially of a peptide having an amino acid sequence as set forth in SEQ. ID. NO. 1, and returning plasma so treated to the ~~patient~~ subject.

12. (Previously presented) The method of Claim 11, wherein the peptide is coupled to the column using a coupling buffer.

13. (Previously presented) The method of Claim 11, wherein the column is a N-hydroxysuccinimide (NHS-) – activated highly cross linked 4% agarose column.

14. Canceled.